Octaviant Financial Introduces Specialized Loan and Therapeutic Warranty Solutions to Help BioPharma, Payers and Insurers Expand Access to Innovative Therapies
New Brunswick, New Jersey–(Newsfile Corp. – December 12, 2022) – Octaviant Financial Announces the Creation of Novel Payment Solutions for High Cost Therapies.
To view the full announcement, including downloadable images, bios, and more, click here.
- Octaviant Financial is leveraging the CMS 2020 Final Rule to bring therapeutic warranties and innovative financing arrangements to market to bridge the gap between innovative therapies and patients, payers and BioPharma companies.
- The OFX product’s key proprietary feature is that it combines a specialized loan with warranty. Loans and warranties are transferable from payer or payer, mitigating the exposure to any single payer in the case of change in employment.
- Gene therapies for more common diseases like sickle cell and diabetes (USD 1,000,000+) are on the horizon.
Click image above to view full announcement.
Octaviant Financial’s mission is to assist drug developers, payers, and providers make innovative treatments, such as gene and cell therapies, as accessible as possible for patients living with rare disease. We strive to provide next generation benefit designs that leverage the latest guidelines regulating the pricing and reimbursement of pharmaceutical goods. Life-changing treatments, such as gene and cell therapies, have the potential to change how we think about medicine, namely, absorbing a high upfront cost for a single treatment that holds the promise of curing patients, minimizing reliance on recurring doses, and ultimately reducing the overall financial burden on the healthcare system.
Source: octaviantFinancial, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/147659